Clinical Trial Update: A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label dose-escalation safety study of INCAGN01949 in subjects with advanced or metastatic solid tumors completed, with results posted on May 12, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• INCAGN01949

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Advanced Malignancies, Metastatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-12